Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic

AbstractBackground. Treatment with immune checkpoint blockade (ICB) with agents such as anti-programmed cell death protein 1 (PD-1), anti-programmed death-liga

Saved in:

Bibliographic Details
Main Authors:	Chan, Timothy A. (Author) , Yarchoan, M. (Author) , Jaffee, E. (Author) , Swanton, C. (Author) , Quezada, S. A. (Author) , Stenzinger, Albrecht (Author) , Peters, S. (Author)
Format:	Article (Journal)
Language:	English
Published:	2019
In:	Annals of oncology Year: 2018, Volume: 30, Issue: 1, Pages: 44-56
ISSN:	1569-8041
DOI:	10.1093/annonc/mdy495
Online Access:	Verlag, Volltext: https://doi.org/10.1093/annonc/mdy495 Verlag, Volltext: https://academic.oup.com/annonc/article/30/1/44/5160130
Author Notes:	T.A. Chan, M. Yarchoan, E. Jaffee, C. Swanton, S.A. Quezada, A. Stenzinger & S. Peters

Description
Summary:	AbstractBackground. Treatment with immune checkpoint blockade (ICB) with agents such as anti-programmed cell death protein 1 (PD-1), anti-programmed death-liga
Item Description:	Published: 05 November 2018 Gesehen am 25.06.2019
Physical Description:	Online Resource
ISSN:	1569-8041
DOI:	10.1093/annonc/mdy495